Shares of Inovio Pharmaceuticals (NASDAQ: INO) today spiked 30% high during premarket trading to a high of $22.85 after announcing that its COVID-19 vaccine had shown positive results in non-human trials.
The results published today showed that its coronavirus DNA vaccine INO-4800 had positive results in a preclinical trial conducted on non-human primates. The results have been submitted to a peer-reviewed journal showing that the company believes that they will pass the review process.
Inovio share price
Dr J. Joseph Kim, INOVIO’s President and CEO, said, “All other previously reported NHP vaccine protection studies actually challenged the animals at the peak of their immune response.”
Adding that: “Our study demonstrates that INO-4800 could provide protection in a more real-world setting, where vaccine-generated memory immune responses protected NHPs for more than 3 months (13 weeks) from the last vaccination.”